In conclusion, we have unraveled the ACSL3-LPIAT1 metabolic axis as a requirement for prostaglandin production and tumorigenesis in NSCLC that could be exploited for therapeutic intervention. This evidence concerns the gene ACSL3 and non-small cell lung carcinoma.